Citation Impact
Citing Papers
Clinical Pharmacokinetics of the Newer ACE Inhibitors
1990
Current and Future Drug Targets in Weight Management
2010
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects
1999
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
2018 Standout
Calcineurin Inhibitor Nephrotoxicity
2009 Standout
Non-Transgenic Mouse Models of Kidney Disease
2016 Standout
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
2009 Standout
Effect of chronic enalapril treatment on enzymes responsible for the catabolism of angiotensin I and formation of angiotensin II
1990
Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment
2018 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Age‐related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications
2003 Standout
Radioimmunoassay for immunoreactive [des-Leu10]-angiotensin I
1989
Multiple roles of adrenomedullin revealed by animal models
2002 StandoutNobel
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
Mice with Cardiac-Restricted Angiotensin-Converting Enzyme (ACE) Have Atrial Enlargement, Cardiac Arrhythmia, and Sudden Death
2004 StandoutNobel
Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
2014
A within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care—an international randomised controlled trial
2012 Standout
Pharmacological management of appetite expression in obesity
2010
Blood Pressure, Cardiac, and Renal Responses to Salt and Deoxycorticosterone Acetate in Mice
2002
Gut hormones: Implications for the treatment of obesity
2009
Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure
2003
CNS-targets in control of energy and glucose homeostasis
2009
Hemodynamic, Hormonal, and Renal Effects of Short-Term Adrenomedullin Infusion in Healthy Volunteers1
2000
European Guidelines for Obesity Management in Adults
2015 Standout
Prediabetes: a high-risk state for diabetes development
2012 Standout
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
2010 Standout
A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9
2000 Standout
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
Blood Pressure–Independent Cardiac Hypertrophy Induced by Locally Activated Renin-Angiotensin System
1998
Gut Peptides: Targets for Antiobesity Drug Development?
2009
Adrenomedullin gene expression differences in mice do not affect blood pressure but modulate hypertension-induced pathology in males
2007 StandoutNobel
Angiotensin-Converting Enzyme Inhibition Improves Vascular Function in Rheumatoid Arthritis
2008
Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial.
1989
Angiotensin-Converting Enzyme C-Terminal Catalytic Domain Is the Main Site of Angiotensin I Cleavage In Vivo
2007 StandoutNobel
Guidelines for the Primary Prevention of Stroke
2014 Standout
The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline
2016 Standout
The Metabolic Syndrome
2008 Standout
Surgery for weight loss in adults
2014 Standout
Activity Assays and Immunoassays for Plasma Renin and Prorenin: Information Provided and Precautions Necessary for Accurate Measurement
2009
Aliskiren Reduces Blood Pressure and Suppresses Plasma Renin Activity in Combination With a Thiazide Diuretic, an Angiotensin-Converting Enzyme Inhibitor, or an Angiotensin Receptor Blocker
2006
Works of Lata Kler being referenced
Stimulation of Cholecystokinin-A Receptors With GI181771X does not Cause Weight Loss in Overweight or Obese Patients
2007
Pharmacokinetics of the Converting Enzyme Inhibitor Cilazapril in Normal Volunteers and the Relationship to Enzyme Inhibition: Development of a Mathematical Model
1987
Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers.
1987
Effects of Single Doses of the Converting Enzyme Inhibitor Cilazapril in Normal Volunteers
1987
Repeated Administration of the Converting Enzyme Inhibitor Cilazapril to Normal Volunteers
1987
Randomized efficacy and safety trial of once‐daily remogliflozin etabonate for the treatment of type 2 diabetes
2014